Oncternal Therapeutics Q3 EPS $(0.17) Misses $(0.14) Estimate, Sales $179.00K Beat $120.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Oncternal Therapeutics reported Q3 losses of $(0.17) per share, missing the analyst consensus estimate of $(0.14) by 21.43%. However, the company's quarterly sales of $179.00K beat the analyst consensus estimate of $120.00K by 49.17%. This represents a 19.05% increase in losses and a 53.14% decrease in sales compared to the same period last year.
November 09, 2023 | 9:48 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oncternal Therapeutics' Q3 earnings missed estimates, but sales exceeded expectations. This mixed result could lead to uncertainty in the market.
Oncternal Therapeutics' Q3 earnings report shows a miss on EPS but a beat on sales. This mixed result could lead to uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100